LIFESTYLE

"Did they intentionally delay the approval of new drugs to avoid giving money?"... BMS is held back by a $6.7 billion lawsuit.

Bristol Myers Squibb (BMS), a major U.S. pharmaceutical company, is facing a hefty 6.7 billion USD lawsuit from former Celgene shareholders. A federal court has ruled that the trial must proceed, addressing allegations that BMS deliberately delayed d

Global Pharma Giants Join Samsung Biologics in Major Climate Pledge to Cut Supply-Chain Emissions by 2030

Samsung Biologics released a joint public letter with seven global pharmaceutical companies as part of the Health Systems Task Force within the Sustainable Markets Initiative (SMI). As the chair of the supply chain sector in SMI, Samsung Biologics ai

GAME OVER: Samsung Biologics Declares War With 'ExellenS'—A Standard That Kills All Biotech Competition

Samsung Biologics is set to launch its next-generation contract development and manufacturing (CDMO) service standard, ExellenS, in Europe. The company intends to showcase how it has leveraged the expertise gained from operating its first four plants

Chinese & Indian Medical Invasion: Pharmaceutic Dependency on Risk of Essential Medicine Supply

Concerns are mounting over the domestic active pharmaceutical ingredient (API) industry's persistent vulnerability and reliance on foreign sources. The concentration of key imports from China and India raises red flags about potential disruptions to

Samsung Biologics Targets Japan's $12.3 Billion CDMO Market: What You Need to Know

Japan is a crucial market for Samsung Biologics to sustain its growth trajectory. We are intensifying our efforts to secure contracts with Japanese pharmaceutical and biotech firms. John Rim, CEO of Samsung Biologics, held a press conference near the

Lotte Biologics Unveils Dual-Site Strategy: A Game Changer for Global CDMO in 2027

The global pharmaceutical and biotech industry is undergoing rapid transformation, driven by three key factors: geopolitical dynamics, evolving funding landscapes, and the emergence of cutting-edge technologies. The U.S. Biosecurity Act has elevated

From R&D to Global Blockbuster: Fexuclue Sparks a New Vision for Daewoong

The success of Fexuclue (generic name: fexuprazan) is the result of close collaboration across all departments—from development and clinical trials to marketing and sales—working as a unified team. This achievement, made possible by Daewoong Pharmace

Fever's Bigger Risk: Why the Tylenol Controversy Puts Moms in a Bind

Controversy is brewing over claims that acetaminophen, the active ingredient in Tylenol commonly used by pregnant women for pain and fever relief, may increase the risk of autism. However, regulatory agencies and academic institutions continue to ass

Celltrion's 'Psoriasis' Biosimilar Poised to Challenge Big Pharma with Phase 1 Data

On September 17, the 34th European Academy of Dermatology and Venereology (EADV) conference kicked off in Paris, France, drawing more than 16,000 attendees from over 120 countries. The event featured global biopharmaceutical companies, including big

Bio-Revolution: Celltrion's $700M Biosimilar Is Reshaping the Global Drug Market

Celltrion has revolutionized the biotech industry by developing the world’s first antibody biosimilar. Despite initial skepticism regarding the feasibility of creating biosimilars for complex monoclonal antibodies, Celltrion’s breakthrough has ushere